Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study

Interleukin 18 ◽

Dose Escalation Study

Phase I Dose-Escalation Study to Determine the Maximum Tolerated Dose (Mtd) of Nintedanib (Bibf 1120) in Combination with Carboplatin/Pegylated Liposomal Doxorubicin (Pld) in Patients (Pts) with Recurrent Ovarian Cancer (Roc)

Annals of Oncology ◽

10.1093/annonc/mdu338.15 ◽

2014 ◽

Vol 25 ◽

pp. iv310

Author(s):

J.M. Del Campo ◽

B. Pardo Búrdalo ◽

V. Rodriguez Freixinos ◽

L. Gaba Garcia ◽

M. Gil Martín ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Dose Escalation ◽

Liposomal Doxorubicin ◽

Maximum Tolerated Dose ◽

Dose Escalation Study ◽

Bibf 1120

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx®) in combination with topotecan in patients with advanced malignancies

Investigational New Drugs ◽

10.1007/s10637-006-7520-2 ◽

2006 ◽

Vol 24 (5) ◽

pp. 413-421 ◽

Cited By ~ 3

Author(s):

Hervé Ghesquières ◽

Sandrine Faivre ◽

Latifa Djafari ◽

Patricia Pautier ◽

Catherine Lhommé ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Liposomal Doxorubicin ◽

Dose Escalation Study ◽

Advanced Malignancies

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)

Investigational New Drugs ◽

10.1007/s10637-013-0011-3 ◽

2013 ◽

Vol 31 (6) ◽

pp. 1499-1504 ◽

Cited By ~ 10

Author(s):

Philipp Harter ◽

Jalid Sehouli ◽

Rainer Kimmig ◽

Jörn Rau ◽

Felix Hilpert ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Liposomal Doxorubicin ◽

Study Group

A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study)

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-014-2418-8 ◽

2014 ◽

Vol 73 (5) ◽

pp. 895-901 ◽

Cited By ~ 7

Author(s):

Tadahiro Shoji ◽

Eriko Takatori ◽

Yoshitaka Kaido ◽

Hideo Omi ◽

Yoshihito Yokoyama ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Study ◽

Liposomal Doxorubicin ◽

Gynecologic Cancer ◽

Recurrent Ovarian Cancer

A phase I study of pegylated liposomal doxorubicin + gemcitabine in a fixed dose-rate infusion for the treatment of patients with recurrent ovarian cancer

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.5579 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 5579-5579

Author(s):

G. Crespo ◽

M. Sierra ◽

R. Losa ◽

N. Villanueva ◽

J. Fra ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Study ◽

Liposomal Doxorubicin ◽

Fixed Dose ◽

Fixed Dose Rate ◽

Fixed Dose Rate Infusion ◽

Rate Infusion

A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)

Annals of Oncology ◽

10.1093/annonc/mdy285.153 ◽

2018 ◽

Vol 29 ◽

pp. viii337 ◽

Cited By ~ 4

Author(s):

R.E. O’Cearbhaill ◽

A. Wolfer ◽

P. Disilvestro ◽

D.M. O’Malley ◽

P. Sabbatini ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Liposomal Doxorubicin ◽

Platinum Resistant

A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.05.001 ◽

2018 ◽

Vol 150 (1) ◽

pp. 23-30 ◽

Cited By ~ 25

Author(s):

Clemens B. Tempfer ◽

Urs Giger-Pabst ◽

Veronika Seebacher ◽

Miriam Petersen ◽

Askin Dogan ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Peritoneal Carcinomatosis ◽

Dose Escalation ◽

Open Label ◽

Dose Escalation Study ◽

Label Dose

8051 Final results of a phase I study of pegylated liposomal doxorubicin + gemcitabine in prolonged infusion in patients with recurrent ovarian cancer less than one year

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71573-3 ◽

2009 ◽

Vol 7 (2) ◽

pp. 464

Author(s):

A.J. Lacave ◽

G. Crespo ◽

P.J. Fonseca ◽

N. Villanueva ◽

J.P. Berros ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Study ◽

Liposomal Doxorubicin ◽

Prolonged Infusion ◽

One Year

A GINECO phase I study evaluating lenalidomide (Le) combined with pegylated liposomal doxorubicin (PLD) and carboplatin (C) in late (>6 months) recurrent ovarian cancer (LROC) patients (pts).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5530 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5530-5530

Author(s):

Frédéric Selle ◽

Anne Lesoin ◽

Marie-Christine Kaminsky ◽

Philippe Follana ◽

Isabelle Ray-Coquard ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Phase I Study ◽

Liposomal Doxorubicin ◽

Recurrent Ovarian Cancer

A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC): Genomic sequencing and updated efficacy results

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.06.086 ◽

2020 ◽

Vol 159 ◽

pp. 41

Author(s):

R.E. O'Cearbhaill ◽

K. Homicsko ◽

A. Wolfer ◽

P.A. DiSilvestro ◽

D.M. O'Malley ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase I ◽

Liposomal Doxorubicin ◽

Genomic Sequencing ◽

Platinum Resistant